The role of isoprenoids in vascular smooth muscle: Potential benefits of statins unrelated to cholesterol lowering

Journal of Human Hypertension

Volumn 10, Issue 6, 1996, Pages 387-390

  Hughes, A D ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

HMG CoA reductase; Isoprenoids; ras; rho; Vascular smooth muscle

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYPOCHOLESTEROLEMIC AGENT; ISOPRENOID; STATIN;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; RISK FACTOR; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ENZYME INHIBITORS; FATTY ACIDS, MONOUNSATURATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LOVASTATIN; MUSCLE, SMOOTH, VASCULAR; PRAVASTATIN; SIMVASTATIN;

EID: 0029796276     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (37)

1. Gotto AMJ. Lipid lowering, regression and coronary events. A review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council Meeting. Circulation 1995; 92: 646-656.
2. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease. NEJM 1995; 332: 512-521.
3. Brown AG et al. Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. J Chem Soc Perkin 1976; 1: 1165-1170.
4. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 1994; 16: 366-385.
5. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-430.
6. Maltese WA. Posttranslational modification of proteins by isopreoids in mammalian cells. FASEB J 1990; 4: 3319-3328.
7. Casey PJ. Protein lipidation in cell signaling. Science 1995; 268: 221-225.
8. Marshall CJ. Protein prenylation: a mediator of protein-protein interactions. Science 1993; 259: 1865-1866.
9. Newman C, Magee AI. Posttranslational processing of the ras superfamily of small GTP-binding proteins. Biochim Biophys Acta 1993; 1155: 79-96.
10. Sinensky M, Lutz RJ. The prenylation of proteins. Bioessays 1992; 14: 25-31.
11. Clarke S. Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu Rev Biochem 1992; 61: 355-386.
12. Roullet JB et al. Mevalonate availability and cardiovascular functions. Proc Natl Acad Sci USA 1993; 90: 11728-11732.
13. Roullet J et al. Mevalonate availability affects human and rat resistance vessel function. J Clin Invest 1995; 96: 239-244.
14. Casey PJ. Lipid modifications of G proteins. Curr Opin Cell Biol 1994; 6: 219-225.
15. Hirata K et al. Involvement of rho p21 in the GTP-enhanced calcium ion sensitivity of smooth muscle contraction. J Biol Chem 1992; 267: 8719-8722.
16. 2+ responsiveness of smooth muscle contraction. FEBS Lett 1993; 324: 211-215.
17. Habenicht AJ, Gomset JA, Ross R. Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and Swiss 3T3 cells stimulated to divide by platelet-derived growth factor. J Biol Chem 1980; 255: 5134-5140.
18. Falke P, Mattiasson I, Stavenow L, Hood B. Effects of a competitive inhibitor (mevinolin) of 3-hydroxy-3-methylglutaryl coenzyme A reductase on human and bovine endothelial cells, fibroblasts and smooth muscle cells in vitro. Pharmacol Toxicol 1989; 64: 173-176.
19. Corsini A et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atheroscler 1993; 101: 117-125.
20. Munro E et al. Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis. Eur J Clin Invest 1994; 24: 766-772.
21. Corsini A et al. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol 1995; 76: 21A-28A.
22. 2+],) elevation by angiotensin II (AII) and platelet derived growth factor-BB (PDGF-BB) in human vascular smooth muscle cells (VSMCs). Biochem Soc Trans 1995; 23: 170S.
23. Maruta H, Burgess AW. Regulation of the Ras signalling network. Bioessays 1994; 16: 489-496.
24. Boguski MS, McCormick F. Proteins regulating ras and its relatives. Nature 1993; 366: 643-654.
25. Irani K, Herzlinger S, Finkel T. Ras proteins regulate multiple mitogenic pathways in A10 vascular smooth muscle cells. Biochem Biophys Res Commun 1994; 202: 1252-1258.
26. Kundra V, Anand-Apte B, Feig L, Zetter BR. The chemotactic response to PDGF-BB: evidence of a role for ras. J Cell Biol 1995; 130: 725-731.
27. Indolfi C, Avvedimento EV, Rapacciuolo A, Di Lorenzo E. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nature Medicine 1995; 1: 541-545.
28. Takai Y, Sasaki T, Tanaka K, Nakanishi H. Rho as a regulator of the cytoskeleton. TIBS 1995; 20: 227-231.
29. Nobes CD, Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 1995; 81: 53-62.
30. Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science 1995; 269: 1270-1272.
31. Zhu BQ et al. Effects of lovastatin on suppression and regression of atherosclerosis in lipid-fed rabbits. J Cardiovasc Pharmacol 1992; 19: 246-255.
32. Gellman J et al. Effect of lovastatin on intimal hyperplasia after balloon angioplasty. A study in an atherosclerotic hypercholesterolemic rabbit. J Am Coll Cardiol 1991; 17: 251-259.
33. Soma MR et al. Inhibition of isoprenoid biosynthesis and arterial smooth-muscle cell proliferation. J Cardiovasc Pharmacol 1995; 25 (Suppl 4): S20-S24.
34. Massy ZA, Keane WF, Kasiske BL. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet 1996; 347: 102-103.
35. Gebhard RL et al. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on human gut mucosa. Lipids 1991; 26: 492-494.
36. Kohl NE et al. Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. J Cell Biochem 1995; Supplementum 22: 145-150.
37. Kohl NE et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA 1994; 91: 9141-9145.